An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (ICON8)

Trial ID # NCT01654146; ICON8
Phase III
Drug Class Chemotherapy
Drug Name Carboplatin
Alternate Drug Names Paraplatin, Novoplatinum
Drugs in Trial Carboplatin, Paclitaxel
Eligible Participant

Newly diagnosed stage IC-IV epithelial ovarian cancer

Patients Enrolled

1566 (20% stage IC-II, 60% stage III, 20% stage IV)

Therapy Setting


Study Design

Open-Label, Randomized


PFS, OS, evaluated per RECIST


Standard of Care (SoC): CarboPt AUC5 or AUC6+Pac 175mg/m2 every 3 weeks
CarboPt q3w+Pac qw: CarboPt AUC5 or AUC6 every 3 weeks+Pac 80mg/m2 weekly
CarboPt+Pac qw: CarboPt AUC2+Pac 80mg/m2 weekly

SoC (n=522) vs CarboPt q3w (n=523) +Pac qw vs CarboPt+Pac qw (n=521):

PFS: 25 vs 25.8 vs 25.9 months
OS: 47.4 vs 54.8 vs 53.4 months, HR: 0.87 (0.73-1.05); HR: 0.91 (0.76-1.09)

Exploratory analysis, patients planned for neoadjuvant chemotherapy followed by IDS w/ RECIST and/or GCIG CA125-evaluable disease:
RECIST (n=564): ORR: 62%; PFS: 14.4 (CR or PR) vs 13.3 months (SD); R0 obtained: 56 (CR or PR) vs 42% (SD)
GCIG-CA125 (n=727): ORR: 84%; PFS: 13.8 (w/ CA125 response) vs 9.7 months (w/o CA125 response); R0 obtained: 50 (w/ CA125 response) vs 30% (w/o CA125 response)

Clinically Significant Adverse Events

SoC vs CarboPt q3w+Pac qw vs CarboPt+Pac qw:
Serious AE:
Grade 3-4 AE: anemia (6 vs 12 vs 5%), decreased neutrophil counts (14 vs 35 vs 30%), decreased white blood cells (5 vs 16 vs 14%)


Weekly dose-dense chemotherapy can be delivered successfully as first-line treatment for epithelial ovarian cancer but does not significantly improve PFS compared with standard chemotherapy every 3 weeks


Clamp AR et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet (2019) 394(10214):2084-2095

Morgan RD et al. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol (2021) 22(2):277-288

Clamp AR et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet (2022) 23(7):919-930

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.